Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rutger H A Folmer

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Drug Discovery Today|January 31, 2016
Integrating biophysics with HTS-driven drug discovery projectsRutger H A Folmer
Drug Discovery Today|August 8, 2017
Drug target residence time: a misleading conceptRutger H A Folmer
Biochemistry|November 27, 2002
Crystal structure and NMR studies of the apo SH2 domains of ZAP-70: two bikes rather than a tandemRutger H A Folmer, Stefan Geschwindner, Yafeng Xue
Computational and Structural Biotechnology Journal|February 22, 2019
Bivalent Ligands for Protein Degradation in Drug DiscoveryMarcel Scheepstra, Koen F W Hekking, Luc van Hijfte, et al.
Journal of Medicinal Chemistry|November 8, 2007
Discovery of a novel warhead against beta-secretase through fragment-based lead generationStefan Geschwindner, Lise-Lotte Olsson, Jeffrey S Albert, et al.
Biochemical and Biophysical Research Communications|August 3, 2005
Interaction of the replication terminator protein of Bacillus subtilis with DNA probed by NMR spectroscopyAdam F Hastings, Gottfried Otting, Rutger H A Folmer, et al.
Journal of Medicinal Chemistry|March 18, 2008
Novel prostaglandin D synthase inhibitors generated by fragment-based drug designMorten Hohwy, Loredana Spadola, Britta Lundquist, et al.
Nature|June 15, 2007
Exploitation of structural and regulatory diversity in glutamate racemasesTomas Lundqvist, Stewart L Fisher, Gunther Kern, et al.
SLAS Discovery : Advancing Life Sciences R & D|October 30, 2016
Unified Software Solution for Efficient SPR Data Analysis in Drug ResearchGöran Dahl, Stephan Steigele, Per Hillertz, et al.
Current Topics in Medicinal Chemistry|November 6, 2007
An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmesJeffrey S Albert, Niklas Blomberg, Alexander L Breeze, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Drug Discovery Today|January 31, 2016
Integrating biophysics with HTS-driven drug discovery projectsRutger H A Folmer
Drug Discovery Today|August 8, 2017
Drug target residence time: a misleading conceptRutger H A Folmer
Biochemistry|November 27, 2002
Crystal structure and NMR studies of the apo SH2 domains of ZAP-70: two bikes rather than a tandemRutger H A Folmer, Stefan Geschwindner, Yafeng Xue
Computational and Structural Biotechnology Journal|February 22, 2019
Bivalent Ligands for Protein Degradation in Drug DiscoveryMarcel Scheepstra, Koen F W Hekking, Luc van Hijfte, et al.
Journal of Medicinal Chemistry|November 8, 2007
Discovery of a novel warhead against beta-secretase through fragment-based lead generationStefan Geschwindner, Lise-Lotte Olsson, Jeffrey S Albert, et al.
Biochemical and Biophysical Research Communications|August 3, 2005
Interaction of the replication terminator protein of Bacillus subtilis with DNA probed by NMR spectroscopyAdam F Hastings, Gottfried Otting, Rutger H A Folmer, et al.
Journal of Medicinal Chemistry|March 18, 2008
Novel prostaglandin D synthase inhibitors generated by fragment-based drug designMorten Hohwy, Loredana Spadola, Britta Lundquist, et al.
Nature|June 15, 2007
Exploitation of structural and regulatory diversity in glutamate racemasesTomas Lundqvist, Stewart L Fisher, Gunther Kern, et al.
SLAS Discovery : Advancing Life Sciences R & D|October 30, 2016
Unified Software Solution for Efficient SPR Data Analysis in Drug ResearchGöran Dahl, Stephan Steigele, Per Hillertz, et al.
Current Topics in Medicinal Chemistry|November 6, 2007
An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmesJeffrey S Albert, Niklas Blomberg, Alexander L Breeze, et al.
Pageof 2